首页> 外文期刊>Antimicrobial agents and chemotherapy. >Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals.
【24h】

Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals.

机译:Ambler A类产生广谱β-内酰胺酶的大肠杆菌和克雷伯菌属。在加拿大的医院。

获取原文
获取原文并翻译 | 示例
           

摘要

This report describes a study carried out to gain baseline information on the molecular characteristics of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in Canada. A total of 29,323 E. coli and 5,156 Klebsiella sp. isolates were screened at 12 participating sites. Of these, 505 clinically significant, nonrepeat isolates displaying reduced susceptibility to the NCCLS-recommended beta-lactams were submitted to a central laboratory over a 1-year period ending on 30 September 2000. A total of 116 isolates were confirmed to be ESBL producers. PCR and sequence analysis revealed the presence of TEM-11 (n = 1), TEM-12 (n = 1), TEM-29 (n = 1), TEM-52 (n = 4), CTX-M-13 (n = 1), CTX-M-14 (n = 15), CTX-M-15 (n = 11), SHV-2 (n = 2), SHV-2a (n = 12), SHV-5 (n = 6), SHV-12 (n = 45), and SHV-30 (n = 2). Five novel beta-lactamases were identified and designated TEM-115 (n = 2), TEM-120 (n = 1), SHV-40 (n = 2), SHV-41 (n = 4), and SHV-42 (n = 1). In addition, no molecular mechanism was identified for five isolates displaying an ESBL phenotype. Macrorestriction analysis of all ESBL isolates was conducted, as was restriction fragment length polymorphism analysis of plasmids harboring ESBLs. Although a "clonal" distribution of isolates was observed at some individual sites, there was very little evidence suggesting intrahospital spread. In addition, examples of identical or closely related plasmids that were identified at geographically distinct sites across Canada are given. However, there was considerable diversity with respect to plasmid types observed.
机译:本报告描述了一项研究,旨在获得有关产生广谱β-内酰胺酶(ESBL)的大肠杆菌和克雷伯菌属的分子特征的基线信息。在加拿大。总共29,323大肠杆菌和5,156克雷伯菌。在12个参与地点筛选了分离株。其中,到2000年9月30日结束的1年期间,将505个临床上显着的,非重复的,对NCCLS推荐的β-内酰胺类药物敏感性降低的分离株提交给中央实验室。已确认共有116个分离株是ESBL的生产者。 PCR和序列分析显示存在TEM-11(n = 1),TEM-12(n = 1),TEM-29(n = 1),TEM-52(n = 4),CTX-M-13(n = 1)。 n = 1),CTX-M-14(n = 15),CTX-M-15(n = 11),SHV-2(n = 2),SHV-2a(n = 12),SHV-5(n = 6),SHV-12(n = 45)和SHV-30(n = 2)。鉴定出五种新颖的β-内酰胺酶并命名为TEM-115(n = 2),TEM-120(n = 1),SHV-40(n = 2),SHV-41(n = 4)和SHV-42( n = 1)。另外,未鉴定出显示ESBL表型的五个分离物的分子机制。对所有ESBL分离物进行了宏观限制性分析,对带有ESBLs的质粒进行了限制性片段长度多态性分析。尽管在某些个体部位观察到了分离株的“克隆”分布,但几乎没有证据表明医院内扩散。此外,还提供了在加拿大各地地理上不同的地点鉴定出的相同或紧密相关的质粒的例子。但是,观察到的质粒类型有相当大的多样性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号